- Home
- FMY vs LSB Comparison
FMY vs LSB Comparison
Compare FMY & LSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- LSB
- Stock Information
- Founded
- FMY 2005
- LSB 2002
- Country
- FMY United States
- LSB China
- Employees
- FMY N/A
- LSB N/A
- Industry
- FMY Finance/Investors Services
- LSB
- Sector
- FMY Finance
- LSB
- Exchange
- FMY Nasdaq
- LSB NYSE
- Market Cap
- FMY 50.9M
- LSB 53.6M
- IPO Year
- FMY N/A
- LSB N/A
- Fundamental
- Price
- FMY $12.10
- LSB $2.23
- Analyst Decision
- FMY
- LSB
- Analyst Count
- FMY 0
- LSB 0
- Target Price
- FMY N/A
- LSB N/A
- AVG Volume (30 Days)
- FMY 10.1K
- LSB 7.4K
- Earning Date
- FMY 01-01-0001
- LSB 12-19-2024
- Dividend Yield
- FMY 6.98%
- LSB N/A
- EPS Growth
- FMY N/A
- LSB N/A
- EPS
- FMY N/A
- LSB N/A
- Revenue
- FMY N/A
- LSB $79,415,311.00
- Revenue This Year
- FMY N/A
- LSB $39.33
- Revenue Next Year
- FMY N/A
- LSB $75.61
- P/E Ratio
- FMY N/A
- LSB N/A
- Revenue Growth
- FMY N/A
- LSB N/A
- 52 Week Low
- FMY $10.71
- LSB $1.88
- 52 Week High
- FMY $12.17
- LSB $11.20
- Technical
- Relative Strength Index (RSI)
- FMY 52.99
- LSB 40.56
- Support Level
- FMY $12.01
- LSB $2.10
- Resistance Level
- FMY $12.16
- LSB $2.49
- Average True Range (ATR)
- FMY 0.11
- LSB 0.22
- MACD
- FMY -0.00
- LSB 0.00
- Stochastic Oscillator
- FMY 59.79
- LSB 16.35
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.